Please login to the form below

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs.

As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol...

Read the full article: 
https://www.researchpartnership.com/news/2017/11/living-with-nash-an-unexpected-diagnosis/


1st December 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Live webinar: Influencing HCP behaviours – Is now the perfect opportunity?
Putting behavioural science at the forefront of market research
Research Partnership
Quantitative specialist joins Research Partnership, London
Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London
Research Partnership
Webcast
Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights
Research Partnership
Webcast
The power of a good story: Turn your insights into effective storytelling with data visualisation
Research Partnership
Article
How will COVID-19 affect uptake of vaccinations against other diseases?
Research Partnership
Podcast
Living With Chronic Illness (Series one)
Research Partnership